Health Care [ 3/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
NewAmsterdam Pharma CompanyN. V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.
NewAmsterdam Pharma CompanyN. V. is headquartered in Naarden, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | -0.34 Decreased by -13.27% | -0.47 Increased by +27.93% |
| Mar 4, 26 | -0.53 Increased by +42.72% | -0.40 Decreased by -32.74% |
| Nov 5, 25 | -0.61 Decreased by -281.25% | -0.40 Decreased by -51.25% |
| Aug 7, 25 | -0.15 Increased by +60.53% | -0.44 Increased by +65.91% |
| May 8, 25 | -0.30 Increased by +69.70% | -0.44 Increased by +31.82% |
| Feb 26, 25 | -0.93 Decreased by -72.22% | -0.96 Increased by +3.12% |
| Nov 6, 24 | -0.16 Increased by +71.64% | -0.45 Increased by +64.44% |
| Aug 7, 24 | -0.38 Increased by +62.38% | -0.52 Increased by +26.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 3.04 M Increased by +2.08% | -48.44 M Decreased by -22.55% | Decreased by -1.59 K% Decreased by -20.05% |
| Dec 31, 25 | 32.00 K Decreased by -99.75% | -74.92 M Increased by +18.72% | Decreased by -234.13 K% Decreased by -32.34 K% |
| Sep 30, 25 | 348.00 K Decreased by -98.80% | -72.00 M Decreased by -332.54% | Decreased by -20.69 K% Decreased by -36.08 K% |
| Jun 30, 25 | 19.14 M Increased by +740.06% | -17.36 M Increased by +55.48% | Decreased by -90.70% Increased by +94.70% |
| Mar 31, 25 | 2.98 M Increased by +112.56% | -39.53 M Increased by +57.85% | Decreased by -1.33 K% Increased by +80.17% |
| Dec 31, 24 | 12.77 M Increased by +1.49 K% | -92.18 M Decreased by -86.23% | Decreased by -721.71% Increased by +88.29% |
| Sep 30, 24 | 29.11 M Increased by +889.83% | -16.65 M Increased by +64.68% | Decreased by -57.18% Increased by +96.43% |
| Jun 30, 24 | 2.28 M Increased by +32.73% | -39.01 M Decreased by -1.87% | Decreased by -1.71 K% Increased by +23.25% |